Anacetrapib lowers LDL by increasing ApoB clearance in mildly hypercholesterolemic subjects

BACKGROUND. Individuals treated with the cholesteryl ester transfer protein (CETP) inhibitor anacetrapib exhibit a reduction in both LDL cholesterol and apolipoprotein B (ApoB) in response to monotherapy or combination therapy with a statin. It is not clear how anacetrapib exerts these effects; ther...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Invest
Main Authors: Millar, John S., Reyes-Soffer, Gissette, Jumes, Patricia, Dunbar, Richard L., deGoma, Emil M., Baer, Amanda L., Karmally, Wahida, Donovan, Daniel S., Rafeek, Hashmi, Pollan, Laura, Tohyama, Junichiro, Johnson-Levonas, Amy O., Wagner, John A., Holleran, Stephen, Obunike, Joseph, Liu, Yang, Ramakrishnan, Rajasekhar, Lassman, Michael E., Gutstein, David E., Ginsberg, Henry N., Rader, Daniel J.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Clinical Investigation 2015
Assuntos:
Clinical Medicine
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4497759/
https://ncbi.nlm.nih.gov/pubmed/25961461
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI80025
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados